Skip Nav Destination
![]()
You do not currently have access to this content.
Common Blood Tests Predict CAR T-cell Therapy Response in Non-Hodgkin Lymphoma Available to Purchase
May 21, 2025
Major Finding: An inflammatory signature is a prognostic biomarker for CAR T-cell failure in non-Hodgkin lymphoma.
Concept: InflaMix uses results from common blood tests to predict survival and treatment response to CAR T-cell therapy.
Impact: Resolving inflammation prior to CAR T-cell therapy may improve responses in patients with lymphomas.
RSS Feeds